DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 8/14/2024 has been entered.
Information Disclosure Statement
3. The NINE information disclosure statement (IDS) submitted on 8/14/2026 were filed after the mailing date of the notice of allowance mailed on 5/15/2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Election/Restrictions
4. Applicant’s election without traverse of Group 1, claims 28-44 and 49 in the reply filed on 2/2/2026 is acknowledged. Claims 35-48 are withdrawn.
Claim Rejections - 35 USC § 103
5. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
6. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
7. Claims 28-29, 34-35, 38-44 and 49 are rejected under 35 U.S.C. 103 as being unpatentable over (US 2014/0037573 A1) to Eliasof et al. (hereinafter Eliasof) in view of the teachings of (US 2002/0076441 A1) to Shih et al. (hereinafter Shih) and in further view of (US 2014/0271885 A1) to Sill et al. (hereinafter Sill).
Eliasof is directed toward nanoparticles encapsulating water soluble actives comprising a triblock copolymer shell. Eliasof discloses at paragraph [0284] that the cargo is water soluble. Eliasof discloses at paragraph [0378] that the cargo is a therapeutic peptide. Eliasof discloses at paragraph [0360] that the copolymers are made of block copolymers that are hydrophilic and hydrophobic. Eliasof discloses at paragraph [0388] that the copolymer may be a triblock. Eliasof discloses at paragraph [0352] that crosslinking controls the rate of degradability. Eliasof discloses each and every element, but is silent regarding a triblock polymer having two hydrophilic end blocks.
Shih is directed toward nanoparticles encapsulating water soluble actives comprising a triblock copolymer shell. Eliasof and Shih are both directed toward nanoparticles encapsulating water soluble actives comprising a triblock copolymer shell and therefore are analogous art. Shih teaches at paragraph [0049] that the suitable polymeric gel for use with the present invention comprises ABA-or BAB-type block copolymers, where the A-blocks are relatively hydrophobic A polymer blocks comprising a biodegradable polyester, and the B-blocks are relatively hydrophilic and teaches that the blocks can be functionally equivalent.
Sill is directed toward nanoparticles encapsulating water soluble actives comprising a triblock copolymer shell. Eliasof and Sill are both directed toward nanoparticles encapsulating water soluble actives comprising a triblock copolymer shell and therefore are analogous art. Sill teaches at paragraph [0015] that the nanoparticle triblock copolymer shell has hydrophilic ends. Sill teaches at paragraph [0113] that the block copolymer may comprise aspartic acid. Sill teaches at paragraph [0308] that the hydrophobic shell is crosslinked.
It would be obvious to one skilled in the art at the time of the filing of the disclosure of Eliasof in view of the teachings of Shih and Sill to create a triblock nanoparticle that forms a prime facie case of obviousness for claims 28-29, 34-35, 38-44 and 49.
Conclusion
8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEFFREY D WASHVILLE whose telephone number is (571)270-3262. The examiner can normally be reached M-F 9-5.
9. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
10. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached at 571-272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
11. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JEFFREY D WASHVILLE/Primary Examiner, Art Unit 1766